Thermo Fisher Scientific announces collaborations with AstraZeneca, Univ. of Nebraska Medical Center

September 14, 2020  –  Thermo Fisher Scientific (Waltham, MA) announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of solutions for unmet needs in clinical biomarker discovery.

Ongoing and planned studies with both AstraZeneca and the University of Nebraska Medical Center will utilize standardized plasma protein profiling workflows, including Thermo Fisher’s newly developed ultra-high throughput plasma protein profiling (uHTPPP) workflow, for biomarker discovery, for a range of conditions. The standardized workflows consist of automated sample preparation for untargeted and targeted methods in combination with the Thermo Scientific Orbitrap Exploris 480 and Thermo Scientific Orbitrap Exploris 240 mass spectrometers.

The University of Nebraska Medical Center is collaborating with Thermo Fisher’s PMSC to utilize the company’s standardized plasma protein profiling workflows to analyze clinical samples in an aneurysm study. The study is supported by the National Institutes of Health-National Institute on Aging (NIH-NIA) and done in collaboration with Vanderbilt University, the University of Maryland and the University of Wisconsin.

Learn More